Dubai: In-vitro diagnostics (IVD) is the basis of 60 per cent of spending in the health sector worldwide and is widely available in the UAE. These include cardiac biomarkers for early detection of Acute Coronary Syndrome (ACS) and specific hormonal assays to manage oncology and pregnancy care in women.
Recognising the increasing importance of IVD and the latest developments in this field, Roche Days Middle East, in collaboration with UAE’s Ministry of Health, inaugurated a three-day annual conference with participation from health-care specialists and industry experts from the Middle East. This year’s conference focuses on the role of biomarkers in ACS and women’s health.
Moritz Hartmann, General Manager of Roche Diagnostics Middle East (RDME), told Gulf News: “With heart attacks causing one in four deaths in the UAE and a growing awareness of women’s health, it is important to focus on the role IVD plays in better management of these conditions. IVD can help in early detection, accurate diagnosis, prevention and management of a health condition and save unnecessary health spending. Besides, it vouches for safety in issues such as blood donation where it can ensure that only virus-free blood is collected.”
Specialists from the region participated in panel discussions where they discussed and debated the role of different kinds of IVDs in the management of health conditions.